A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Tolero Pharmaceuticals
Enrollment Form
This study is currently enrolling.